

CURRICULUM VITAE

Name GREEN, Alfred Richard
Date of Birth 8th February 1944
Present appointment Honorary Professor of Neuropharmacology, School of Life Sciences, Univ. Nottingham Medical School, Nottingham

Previous Appointments

1996-07 Director, Global Discovery CNS & Pain Control, AstraZeneca R&D, Loughborough
1986-96 Unit Director, Astra Neuroscience Research Unit, London
1982-85 Assistant Director, MRC Unit and University Department of Clinical Pharmacology Unit, Oxford
1973-82 MRC Scientist, Clinical Pharmacology Unit, Oxford.
1970-73 International Visiting Fellow, Laboratory of Preclinical Pharmacology, NIMH, St. Elizabeths Hospital, Washington DC, USA
1966-70 Research Assistant and post-doctoral research assistant, Department of Chemical Pathology, Institute of Neurology, Queen Square, London.
1962-63 Laboratory Assistant, Nicholas Laboratories, Slough.

Degrees and Academic Awards

1966 B.Sc. (London) Joint Honours in Chemistry and Physiology
1969 Ph.D. (London) Biochemistry
1987 D.Sc. (London) Pharmacology
2005 Fellow, British Pharmacological Society
2006 Honorary Member, International Society for Serotonin Research
2010 Lifetime Achievement Award, British Association for Psychopharmacology
2010 President Emeritus, British Pharmacological Society
2013 Honorary Fellow, British Pharmacological Society

Publications

Approximately 320 papers in major journals, 3 books, 40 chapters in books and 120 abstracts in journals or meeting books.

National and International Appointments

Trustee and Councillor, British Pharmacological Society (2014-16)
Member Governance Panel, British Association for Psychopharmacology (2014-16)
Chair, Governance Panel, British Association for Psychopharmacology (2016-18)
Member of Dept Trade and Industry "Foresight" project steering group on psychoactive drugs (2004-05)
Representative of Br Pharmacol Soc to EPHAR (2004-08)
Treasurer/Secretary, Serotonin Club (1997 -2004)
President, Serotonin Club (1994-96)
Vice-President (Europe) Serotonin Club (1992-94)
Member, British National Committee for Pharmacology (1988-90)
Delegate to General Assembly of IUPHAR (1990)
General Secretary, British Pharmacological Society (1989-91)

Meetings Secretary, British Pharmacological Society	(1986-88)
Member, Committee, British Pharmacological Society	(1985-91)
Member, Clinical Committee, British Pharmacological Society	(1986-91)
Member, Council, British Association for Psychopharmacology	(1983-87)
Member, Research Committee of the Mental Health Foundation	(1980-86)

Journal Appointments

British Journal of Pharmacology - Senior Editor	(2006-12)
British Journal of Pharmacology - Editor	(1976-84; 86-91)
British Journal of Clinical Pharmacology - Editor	(1989-91)
European Journal of Pharmacology - Editor	(1986-94)
	-Consultant (1994 -04)
Neuropharmacology	Executive Editor (1979-06)
	Advisory Editor (1976-79)
Psychopharmacology	Managing Editor (1985-06)
	Advisory Editor (1981-84)
Journal of Neural Transmission - Advisory Editor	(1983-86)
Arch. Int. Pharmacodyn. Ther. - Advisory Editor	(1976-90)
Journal of Psychopharmacology - Editor	(1986-91)
Molecular Neuropharmacology - Editor	(1990-92)

Society Membership

British Pharmacological Society
British Association for Psychopharmacology
International Society for Serotonin Research
Society for Medicines Research

Prizes and Awards

1970	Queen Square Prize - awarded for research at the National Hospital, Queen Square, London to any worker under 35 years.
1970	US Public Health Service International Post-doctoral Fellowship; held at National Institute of Mental Health, Washington DC (with Dr E. Costa).
1977	Anna-Monika Foundation International Prize - for research into depressive illness. 2nd prize awarded with Professor D.G. Grahame-Smith for biochemical pharmacological studies.
1977	N.I.H. Consultant Award - to conduct a project at National Institute of Mental Health.
1979	British Council Award - to study in the Dept. Pharmacology, Univ. Göteborg with Professor Arvid Carlsson.
1998	Prestige Lecture, School of Pharmacy, Univ. Bradford
2001	William Evans Visiting Fellow, Univ. Otago, New Zealand
2006	Inaugural Rapport Lecturer, Serotonin Club Meeting, Sapporo, Japan

University Appointments

Hon. Professor of Neuropharmacology, Univ. Nottingham	(2005-)
Hon. Professor of Pharmacology, De Montfort Univ., Leicester	(1998-05)
Visiting Professor, Department of Pharmacology, Imperial College School of Medicine, London	(1991-96)
Recognised Teacher (Pharmacology), Univ. London	(1986-96)
Hon. Senior Lecturer, Institute of Neurology, University of London	(1986-96)
Member of Faculties of Physiological Sciences, Clinical Medicine and Psychological Sciences, University of Oxford	(1978-86)
Lecturer (Pharmacology), Corpus Christi College, Oxford	(1984-91)

Examiner (University of London)

External examiner B.Sc. (Pharmacol.and Biochem.) St. Mary's Hospital, London	(1986-87)
Examiner B.Sc. (Pharmacology), Charing Cross Medical School London	(1988-90)
Examiner B.Sc. (Pharmacology), Kings College, London	(1994-96)

Examiner (University of Oxford)

Final Honours School of Physiological Sciences	(1983-85)
Vice	(1986-88)
Final Honours School of Physiology, Psychology and Philosophy	(1983-85)
Assessor for paper in the BA (Hons) Biochemistry	(1980-81)

Examiner (University of East London)

M.Sc. and Postgrad. Diploma (Pharmacology)	(1993- 96)
--	------------

Examiner (Higher Degrees)

45 PhD and other higher degrees

Supervisor (Higher degrees)

15 PhD and MD

Books and book chapters

Thesis

Green AR

Effects of hydrocortisone and stress on tryptophan metabolism.
PhD Thesis, University of London (1969)

Books

Green AR & Costain DW

Pharmacology and Biochemistry of Psychiatric Disorders. pp 228.
John Wiley & Sons, Chichester (1981, English Edition; 1983, Japanese Edition)

Green AR

Neuropharmacology of Serotonin, pp 456.
(Editor) Oxford University Press, Oxford (1985)

Green, AR & Cross, AJ

Neuroprotective agents and cerebral ischaemia. pp 373
(Editor) Academic Press, London (1997)

Green AR & Haddad P

The British Association for Psychopharmacology: The first 40 years (In
Preparation)

Chapters in Books

Green AR & Grahame-Smith DG

5-Hydroxytryptamine and other indoles in the central nervous system. *Handbook of Psychopharmacology. 3:* 169-245. (Eds: Iversen LL, Iversen SD, & Snyder SH) Plenum Press, New York (1975)

Green AR, Heal DJ & Grahame-Smith DG

Lack of change in the sensitivity of rat caudate nucleus to dopamine when thyrotropin releasing hormone and cycloheximide produce opposite effects on the behavioural responses to certain centrally acting drugs. *Chemical Tools in Catecholamine Research. 2.* (Eds: Almgren O, Carlsson A & Engel J) Elsevier, Amsterdam (1975)

Grahame-Smith DG & Green AR

Some factors regulating the functional activity of 5-hydroxytryptamine. *Metabolic Compartmentation and Neurotransmission.* (Eds: Berl S, Clarke DD & Schneider D). Nato Advanced Study Institute A6: 567-576. Plenum Press, New York (1976)

Green AR & Youdim MBH

Use of behavioural model to study the action of monoamine oxidase inhibition *in vivo.* *Monoamine Oxidase and its Inhibition.* (Eds: Wolstenholme GEW & Knight J) Ciba Foundation Symposium 39: 231-245. Elsevier, Amsterdam (1976)

Youdim MBH, Green AR & Grahame-Smith DG

The role of 5-hydroxytryptamine, dopamine and MAO in the production of the hyperactivity syndrome following MAO inhibition and L-tryptophan. *Recent Advances in the Treatment of Parkinson's Disease.* (Eds: Birkmayer W, Hornykiewicz O) Editions "Roche" 155-162 (1976)

Youdim MBH & Green AR

Biogenic amine metabolism in iron deficient rats - behavioural correlates. *Ciba Foundation Symposium. 51:* 201-221, Elsevier, North Holland (1977)

Youdim MBH, Green AR & Aronson JK

The implications of the effects of tissue iron deficiency on behaviour and drug metabolism. *Anaemia in General Practice—The Place of Haematinics*. pp 37-42. (Ed: Richardson RG) Abbott Labs Ltd. U.K. (1977)

Grahame-Smith DG & Green AR

The effect of electroconvulsive shock on brain monoamine function in the rat. *Depressive Disorders*. pp 141-154. 13th Symposium Medicum Hoechst Schattauer Verlag, Stuttgart (1978)

Green AR

The role of dietary tryptophan in the regulation of brain 5-hydroxytryptamine synthesis and function. *Essays in Neurochemistry and Neuropharmacology*. 3: 103-127. (Ed: Youdim MBH) John Wiley & Sons, Chichester (1978)

Green AR

The control of 5-hydroxytryptamine metabolism and functional activity. *Serotonin in Mental Abnormalities*. pp 71-97. (Ed: Boullin DJ) John Wiley & Sons, Chichester (1978)

Green AR & Costain DW

The biochemistry of depression. *Psychopharmacology of Affective Disorders*. pp. 23-40. (Eds: Paykel ES & Coppen A) Oxford University Press, Oxford (1979)

Green AR, Costain DW, Heal DJ, Atterwill CK & Grahame-Smith DG

Enhanced monoamine behavioural responses following repeated electro-convulsive shock to rats and their relevance to ECT. *Neuropsychopharmacology*. pp 21-29. (Eds: Saletu B, Berner P & Hollister L) Pergamon Press, Oxford (1979)

Green AR, Deakin JFW & Costain DW

Behavioural responses to L-tryptophan and L-DOPA in monoamine oxidase inhibitor treated rats. *Neuropsychopharmacology*. (Eds: Saletu B, Berner P & Hollister L) Pergamon Press, Oxford (1979)

Green AR

Changes in monoamine function in rats after electroconvulsive shocks: possible mechanisms involved and their relevance to ECT. *The Biochemistry of Psychiatric Disturbance*. pp 35-52. (Ed: Curzon G) John Wiley & Sons, Chichester (1980)

Green AR

The possible anti-depressant mechanism of ECT. *Enzymes and Neurotransmitters in Mental Disease*. pp. 445-469. (Eds: Usdin E, Sourkes TL & Youdim MBH) John Wiley & Sons, Chichester (1980) Youdim MBH & Green AR The metabolism and function of monoamines in iron-deficient rats. 4th Int. *Catecholamine Symposium*. (Ed: Usdin E) Pergamon Press, Oxford (1980)

Green AR & Nutt DJ

Antidepressants. *Psychopharmacology*. 1/1: 3-42. (Eds: Grahame-Smith DG, Hippus H & Winokur G) Excerpta Medica, Amsterdam (1982)

Green AR, Nutt DJ & Cowen PJ

The raised seizure threshold following convulsion. *Psychopharmacology of Convulsion*. pp. 16-26. (Ed: Sandler M) Oxford University Press, Oxford (1982)

Green AR & Aronson JK

The influence of tryptophan dose or co-administration of pyridoxine, nicotinamide or allopurinol on the metabolism of an oral L-tryptophan load. *Management of Depression with Monoamine Precursors*. Advances in Biol Psychiat. 10: 67-81. (Eds: Van Praag HM & Mendlewicz J) S Karger, Basel (1983)

Heal DJ, Pycock CJ, Youdim MBH & Green AR

- Actions of TRH and its analogues on the mesolimbic dopamine system. *Thyrotropin Releasing Hormone*. pp 271-282. (Eds: Griffiths E & Bennett GW) Raven Press, New York (1983)
- Grahame-Smith DG, Cowen PJ, Green AR, Heal DJ & Nimgaonkar V
 β -adrenoceptor agonists enhance the functional activity of brain 5-hydroxytryptamine: relationship to antidepressant activity. *Clinical Pharmacology in Psychiatry*. pp 313-326. Macmillan Press, Basingstoke (1984)
- Green AR
 Studies on the possible association between alterations in monoamine-mediated behaviours and biochemical changes which occur after repeated ECS. *Basic Mechanisms of ECT*. pp 5-17. (Eds: Lerer B, Weiner RD & Belamker RH) John Libbey & Co., London (1984)
- Green AR
 Antidepressants new concepts of the mode of action. *Antidepressants: Progress in problem areas*. pp 4-6. Franklin Scientific Projects, London (1984)
- Green AR, Bowdler JM, Cowen PJ, Minchin MCW & Nutt DJ
 Effect of convulsions on seizure threshold and GABA function. *Dynamics of Central Neurotransmitter Function*. pp 211-218. (Ed: Hanin I) Raven Press, New York (1984)
- Green AR, Cowen PJ, Nimgaonkar VL & Grahame-Smith DG
 Effect of β_2 -Adrenoceptor agonists on serotonin biochemistry and function. *Frontiers in Biochemical and Pharmacological Research in Depression*. pp 285-288. Nobel Conference 4, Raven Press, New York (1984)
- Green AR, Nimgaonkar VL & Goodwin GM
 β -Adrenoceptor agonists, ECT and other antidepressants: Effects on serotonin biochemistry and function. *Proceedings of the IX International Congress of Pharmacology*. 3: 117-124. (Eds: Turner P, Mitchell JF & Paton WDM) Macmillan Press, Basingstoke (1984)
- Green AR
 Serotonin neuropharmacology, a review of some current research and clinical implications. *Neuropharmacology of Serotonin*. (Ed: Green AR) pp 409-420. Oxford University Press, Oxford (1985)
- Green AR & Heal DJ
 The effect of drugs on serotonin-mediated behavioural models. *Neuropharmacology of Serotonin*. pp 326-365. (Ed: Green AR) Oxford University Press (1985)
- Green AR & Nutt DJ
 Antidepressants. *Psychopharmacology*. pp 1-34 (Eds: Grahame-Smith DG, Hippus H & Winokur G) Excerpta Medica, Amsterdam (1985)
- Green AR
 Electroconvulsive shock: a GABAergic mechanism? *GABA and mood disorders: animal and clinical studies*. pp 51-60 (Eds: Lloyd KG, Bartholini G & Morselli PL) Raven Press, New York (1986)
- Green AR & Goodwin GM
 Antidepressants and monoamines: actions and interactions. *The Biology of Depression*. pp 174-189 (Ed: Deakin JFW) Gaskell, London (1986)

- Green AR, Heal DJ & Goodwin GM
The effects of electroconvulsive therapy and antidepressant drugs on monoamine receptors in rodent brain: similarities and differences in depression antidepressants and receptor sensitivity. *Ciba Foundation Symposium*. 123: 246-260 (1986)
- Green AR & Goodwin GM
The pharmacology of the hypothermic response of rodents to 8-OH-DPAT administration and the effects of psychotropic drug administration on this response. *Brain serotonergic mechanisms: the pharmacological, biochemical and potential therapeutic action of 8-OH-DPAT and other putative 5-HT1A agonists*. pp 161-176. (Eds: Dourish CT, Hutson PH & Ahlenius S) Ellis-Horwood, Bristol (1987)
- Green AR & Nutt DJ
Psychopharmacology of electroconvulsive therapy. *Handbook of Psychopharmacology*. 19: 375-420 (Eds: Iversen LL, Iversen SD & Snyder SH) Plenum Press, New York (1987)
- Green AR
The possible role of GABA in the mechanism of action of antidepressant drugs. *Topics in neurochemistry and neuropharmacology*. (Eds: Youdim MBH, Lovenberg W & Tipton KF) pp 105-121. Taylor and Francis, London (1989)
- Green AR
The effects of antidepressant drugs on noradrenergic receptor mechanisms in the central nervous system. *Neuropharmacology of Noradrenaline*. (Eds: Heal DJ & Marsden CA) pp 316-348. Oxford University Press, Oxford (1989)
- Green AR
Behavioural pharmacology of 5-HT: an introduction: *Behavioural Pharmacology of 5-HT*. pp. 3-20 (Eds: Bevan P, Cools AR & Archer T) Laurence Erlbaum Assoc. New Jersey (1989)
- Bowen DM, Cross AJ, Francis PT, Green AR, Lowe SL, Procter AW, Steele JE & Stratmann GC
Distribution of neurochemical deficits in Alzheimer's Disease. *Imaging, Cerebral Topography and Alzheimer's Disease*. pp 41-51 (Eds: Rapoport SR, Petit H, Leys D & Christer Y) Springer-Verlag, Berlin (1990)
- Cross AJ, De Souza RJ, Murray TK, Robinson TN & Green AR
Interaction of tetrahydroaminoacridine with cholinergic systems *in vitro* and *in vivo*. *Pharmacological Interventions on Central Cholinergic Mechanisms in Senile Dementia (Alzheimer's Disease)*. (Eds: Kewitz, Thomsen, Bickel). pp 278-279. W Zuckschwerdt Verlag, Munich (1990)
- Baldwin HA, Snares M, Williams JL, Cross AJ & Green AR
Neurochemical consequences of photochemically-induced ischaemia in the rat brain. *Monitoring Molecules in Neuroscience*. pp 499-451. Proceedings of the 5th International conference on *in vivo* methods. (Eds: Rollema H, Westerink BJC, Drijfhout WJ) Centre for Pharmacy, Groningen (1991)
- Bowen DM, Francis PT, Chessell IP, Webster M-T, Proctor AW, Chen C, Qume M, Neary D, Cross AJ & Green AR
Alzheimer's disease: Is the improvement of cholinergic transmission the correct strategy? In: *Alzheimer Disease Therapy*. (Eds: Cutler N & Gottfries CG), pp89-106. John Wiley, Chichester (1995)

Green, AR & Cross, AJ

Techniques for examining neuroprotective drugs in vivo. In *Neuroprotective agents and cerebral ischaemia* (Eds Green AR & Cross AJ) pp47-68. Academic Press, London (1997)

Colado MI & Green AR

Serotonin: 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
Encyclopaedia of Neuroscience (Ed: Squires LR, Elsevier)

Colado MI, O'Shea & Green AR

MDMA and other club drugs. *Handbook of Contemporary Neuropharmacology*
(Eds: Sibley DR, Hanin I, Kuhar, M & Skolnick P. John Wiley & Sons Inc

Journal publications

- Curzon G & Green AR
Effect of hydrocortisone on rat brain 5-hydroxytryptamine. *Life Sci* 7: 657-663 (1968)
- Green AR & Curzon G
Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. *Nature* 220: 1095-1097 (1968)
- Curzon G & Green AR
Effect of immobilisation on rat liver tryptophan pyrrolase and brain 5-hydroxytryptamine metabolism. *Br J Pharmacol* 37: 689-697 (1969)
- Green AR & Curzon G
Effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. *Biochem Pharmacol* 19: 2061-2068 (1970)
- Green AR, Joseph MH & Curzon G
Oral contraceptives, depression and amino acid metabolism. *Lancet* i: 1288 (1970)
- Curzon G & Green AR
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. *Br J Pharmacol* 39: 653-655 (1970)
- Curzon G & Green AR
Regional and subcellular changes in rat brain 5-hydroxytryptamine and 5-hydroxyindoleacetic acid due to hydrocortisone, α -methyltryptophan, l-kynurenine and immobilization. *Br J Pharmacol* 43: 39-52 (1971)
- Boullin DJ, Green AR & Price KS
The mechanism of adenosine diphosphate induced platelet aggregation, binding to platelet receptors and inhibition of binding and aggregation by Prostaglandin E₁. *J Physiol* 221: 415-426 (1972)
- Boullin DJ & Green AR
Mechanisms by which human blood platelets accumulate glycine, GABA and amino acid precursors of putative neurotransmitters. *Br J Pharmacol* 45: 83-94 (1972)
- Boullin DJ, Votavova M & Green AR
Protein synthesis by human blood platelets after accumulation of leucine and arginine and its possible significance *in vivo*. *Thromb diath Haemorrh* 28: 57-64 (1972)
- Costa E, Green AR, Koslow SH, LeFevre HL, Revuelta AV & Wang C
Dopamine and norepinephrine in noradrenergic axons: an *in vivo* study of their precursor-product relationship by mass fragmentography and radiochemistry. *Pharmacol Rev* 24: 769-790 (1972)
- Green AR, Boullin DJ, Massarelli R & Hanin I
Can the human blood platelet be used as a model for the cholinergic neuron? *Life Sci* 11: 1049-1058 (1972)
- Green AR, Koslow SH & Costa E
Identification and quantitation of two new indolealkylamines in rat hypothalamus. *Brain Res* 51: 371-374 (1973)
- Koslow SH & Green AR
Analysis of pineal and brain indolealkylamines by gas chromatography-mass spectrometry. *Adv Biochem Psychopharmacol* 7: 33-43 (1973)

- Grahame-Smith DG & Green AR
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. *Br J Pharmacol* 52: 19-26 (1974)
- Green AR & Grahame-Smith DG
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. *Neuropharmacology* 13: 949-959 (1974)
- Green AR & Grahame-Smith DG
TRH potentiates the behavioural changes following increased brain 5-hydroxytryptamine synthesis in rats. *Nature* 251: 524-526 (1974)
- Green AR & Grahame-Smith DG
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. *Neuropharmacology* 14: 107-113 (1975)
- Green AR & Grahame-Smith DG
Amines, anti-convulsants and epilepsy. *Lancet* i: 639-640 (1975)
- Green AR, Hughes JP & Tordoff AFC
The concentration of 5-methoxytryptamine in rat brain and its effects on behaviour following its peripheral injection. *Neuropharmacology* 14: 601-606 (1975)
- Green AR & Curzon G
Effects of hydrocortisone and immobilization on tryptophan metabolism in brain and liver of rats of different ages. *Biochem Pharmacol* 24: 713-716 (1975)
- Green AR, Sourkes TL & Young SN
Liver and brain tryptophan metabolism following hydrocortisone administration to rats and gerbils. *Br J Pharmacol* 53: 287-292 (1975)
- Green AR, Woods HF, Knott PJ & Curzon G
Factors influencing the effect of hydrocortisone on rat brain tryptophan metabolism. *Nature* 225: 170 (1975)
- Green AR & Youdim MBH
Effects of clorgyline, deprenil and tranylcypromine on rat brain 5-HT concentrations, monoamine oxidase activity and hyperactivity following subsequent tryptophan administration. *Br J Pharmacol* 55: 415-422 (1975)
- Green AR, Woods HF & Joseph MH
Tryptophan metabolism in the isolated perfused rat liver: effects of tryptophan concentration, hydrocortisone and allopurinol on tryptophan pyrrolase activity and kynurenine formation. *Br J Pharmacol* 57: 103-114 (1976)
- Green AR & Kelly PH
Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-dopa. *Br J Pharmacol* 57: 141-147 (1976)
- Green AR & Grahame-Smith DG
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. *Nature* 262: 594-596 (1976)
- Green AR, Youdim MBH & Grahame-Smith DG
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. *Neuropharmacology* 15: 173-179 (1976)
- Green AR & Grahame-Smith DG
The effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. *Nature* 260: 487-491 (1976)

- Evans JPM, Grahame-Smith DG, Green AR & Tordoff AFC
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. *Br J Pharmacol* 56: 193-199 (1976)
- Boullin DJ & Green AR
5-Methoxytryptamine stimulation of 5-HT receptors mediating the rat hyperactivity syndrome and blood platelet aggregation. *Adv Biochem Psychopharmacol* 15: 127-140 (1976)
- Woods HF, Green AR, Youdim MBH & Grahame-Smith DG
Monoamine metabolism in the isolated perfused rat brain. *Biochem Soc Trans* 4: 22-26 (1976)
- Woods HF, Graham CW, Green AR, Youdim MBH, Grahame-Smith DG & Hughes JT
Some histological and metabolic properties of an isolated perfused rat brain preparation with special reference to monoamine metabolism. *Neuroscience* 1: 313-323 (1976)
- Heal DJ, Green AR, Boullin DJ & Grahame-Smith DG
Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine sensitive adenylate cyclase and locomotor activity produced by tranlycypromine and L-tryptophan or L-dopa. *Psychopharmacology* 49: 287-300 (1976)
- Green AR & Woods HF
Tryptophan and depression. Leading article. *Br Med J* i: 242-243 (1976)
- Green AR, Tordoff AFC & Bloomfield MR
Elevation of brain GABA concentrations with amino-oxyacetic acid; effect on the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. *J Neural Transm* 39: 103-112 (1976)
- Green AR, Heal DJ, Grahame-Smith DG & Kelly PH
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. *Neuropharmacology* 15: 591-599 (1976)
- Green AR, Mitchell BD, Tordoff AFC & Youdim MBH
Evidence for dopamine deamination by Type A and Type B monoamine oxidase in rat brain *in vivo* and for the degree of inhibition of the enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. *Br J Pharmacol* 60: 343-349 (1977)
- Green AR, Heal DJ & Grahame-Smith DG
Further observations on the effect of repeated electro-convulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. *Psychopharmacology* 52: 195-200 (1977)
- Boullin DJ, Adams CBT, Mohan J, Green AR, Hunt TM, Du Boulay GH & Rogers AT
Dopamine induced arousal and reversal of cerebral arterial spasm following surgery for clipping of ruptured cerebral aneurysms. *Proc Royal Soc Med* 70: 55-70 (1977)
- Green AR
The treatment of depression. Leading article. *Br Med J* 2: 1105 (1977)

- Green AR
Repeated chlorpromazine administration increases the behavioural responses of rats to 5-hydroxytryptamine receptor stimulation. *Br J Pharmacol* 59: 367-371 (1977)
- Green AR
Repeated exposure of rats to the convulsant agent fluorothyl enhances 5-hydroxytryptamine and dopamine mediated behavioural responses. *Br J Pharmacol* 62: 325-333 (1978)
- Green AR
ECT - how does it work? *Trends in Neurosciences* 1: 57-58 (1978)
- Green AR
Tryptophan metabolism, oral contraceptives and pyridoxine. *Lancet* i: 661-662 (1978)
- Green AR
The neuropharmacology of depression. *Scottish Med J* 23: 66-67 (1978)
- Green AR & Grahame-Smith, DG
Processes regulating the functional activity of brain 5-hydroxytryptamine: results of animal experimentation and their relevance to the understanding and treatment of depression. *Pharmacopsychiat* 11: 3-16 (1978)
- Green AR, Bloomfield MR, Woods HF & Seed M
Metabolism of an oral tryptophan load by women and evidence against the induction of tryptophan pyrrolase by oral contraceptives. *Br J Clin Pharmacol* 5: 233-241 (1978)
- Green AR, Peralta E, Hong JS, Mao CC, Atterwill CK & Costa E
Alterations in GABA metabolism and met-enkephalin concentration in rat brain following repeated electroconvulsive shock. *J Neurochem* 31: 607-611 (1978)
- Green AR
The antidepressant mechanism of electroconvulsive therapy. *Oxford Med School Gazette* 30: 6 (1978)
- Grahame-Smith DG, Green AR & Costain DW
The mechanism of the antidepressant action of ECT. *Lancet* i: 254-257 (1978)
- Heal DJ, Green AR, Bloomfield MR & Grahame-Smith DG
Neuroleptic drugs block the hyperactivity and the increase in caudate nucleus cyclic AMP concentration produced by tranlycypromine and L-dopa administration to rats. *Psychopharmacology* 57: 193-197 (1978)
- Heal DJ, Phillips AG & Green AR
Studies on the locomotor activity produced by injection of dibutyryl cyclic AMP into the nucleus accumbens of rats. *Neuropharmacology* 17: 265-270 (1978)
- Costain DW & Green AR
 β -Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. *Br J Pharmacol* 64: 193-200 (1978)
- Deakin JFW & Green AR
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranlycypromine and L-tryptophan or L-dopa to rats. *Br J Pharmacol* 64: 201-209 (1978)
- Youdim MBH & Green AR
Iron deficiency and neurotransmitter synthesis and function. *Proc Nutr Soc* 37: 123-129 (1978)

- Heal DJ & Green AR
Repeated electroconvulsive shock increases the behavioural responses of rats to injection of both dopamine and dibutyryl cyclic AMP into the nucleus accumbens. *Neuropharmacology* 17: 1085-1087 (1978)
- Heal DJ & Green AR
Administration of thyrotrophin releasing hormone (TRH) to rats releases dopamine in the n.accumbens but not n.caudatus. *Neuropharmacology* 18: 23-31 (1979)
- Costain DW, Green AR & Grahame-Smith DG
Enhanced 5-hydroxytryptamine mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. *Psychopharmacology* 11: 167-170 (1979)
- Youdim MBH, Aronson JK, Blau K, Green AR & Grahame-Smith DG
Tranlycypromine ('Parnate') overdose: measurement of tranlycypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. *Psychol Med* 9: 377-382 (1979)
- Green AR, Bloomfield MR, Atterwill CK & Costain DW
Electroconvulsive shock reduces the cateleptogenic effect of both haloperidol and arecoline in rats. *Neuropharmacology* 18: 447-451 (1979)
- Tye NC, Iversen SD & Green AR
The effects of benzodiazepines and serotonergic manipulations on punished responding. *Neuropharmacology* 18: 689-695 (1979)
- Youdim MBH, Green AR, Bloomfield MR, Mitchell BD, Heal DJ & Grahame-Smith DG
The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rat. *Neuropharmacology* 19: 259-267 (1980)
- Heal DJ, Green AR & Buylaert WA
Inhibition of apomorphine-, bromocriptine- and lergotril-induced circling behaviour by subsequent haloperidol administration. *Neuropharmacology* 19: 133-137 (1980)
- Atterwill CK & Green AR
Responses of developing rats to L-tryptophan plus an MAOI-I: monitoring changes in behaviour, brain 5-HT and tryptophan. *Neuropharmacology* 19: 325-335 (1980)
- Atterwill CK & Green AR
Responses of developing rats to L-tryptophan plus an MAOI-II: effects of repeated electroconvulsive shock. *Neuropharmacology* 19: 337-341 (1980)
- Nutt DJ, Cowen PJ & Green AR
On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock. *Neuropharmacology* 19: 1017-1023 (1980)
- Bowdler JM, Green AR & Rawle FC
Brain and serum calcium concentrations following electroconvulsive shock and bicuculline induced convulsions in rats. *Br J Pharmacol* 71: 321-325 (1980)
- Koblin DD, Little HJ, Green AR, Daniels S, Smith EB & Paton WDM
Brain monoamines and the high pressure neurological syndrome. *Neuropharmacology* 19: 1031-1038 (1980)
- Nutt DJ, Green AR & Grahame-Smith DG
Enhanced 5-hydroxytryptamine and dopamine mediated behavioural responses following convulsion I: the effects of single and repeated bicuculline-induced seizures. *Neuropharmacology* 19: 897-900 (1980)

- Cowen PJ, Nutt DJ & Green AR
Enhanced 5-hydroxytryptamine and dopamine mediated behavioural responses following convulsion II: the effects of anaesthesia and current conditions on the appearance of enhanced responses following electroconvulsive shock. *Neuropharmacology* 19: 901-906 (1980)
- Green AR, Costain DW & Deakin JFW
Enhanced 5-hydroxytryptamine and dopamine mediated behavioural responses following convulsion III: the effects of monoamine antagonist and synthesis inhibitors on the ability of electroconvulsive shock to enhance responses. *Neuropharmacology* 19: 907-914 (1980)
- Green AR, Aronson JK, Curzon G & Woods HF
Metabolism of an oral tryptophan load I: effects of dose and pretreatment with tryptophan. *Br J Clin Pharmacol* 10: 603-610 (1980)
- Green AR, Aronson JK, Curzon G & Woods HF
Metabolism of an oral tryptophan load II: effects of pretreatment with the putative tryptophan pyrolyase inhibitors nicotinamide or allopurinol. *Br J Clin Pharmacol* 10: 611-615 (1980)
- Green AR & Aronson JK
Metabolism of an oral tryptophan load III: effect of a pyridoxine supplement. *Br J Clin Pharmacol* 10: 617-619 (1980)
- Cowen PJ, Nutt DJ & Green AR
Repeated electroconvulsive shock does not increase the susceptibility of rats to a cage convulsant (isopropylbicyclopentylphosphate). *Neuropharmacology* 19: 1025-1026 (1980)
- Green AR & Deakin JFW
Brain noradrenaline depletion prevents ECS-induced enhancement of serotonin- and dopamine-mediated behaviour. *Nature* 285: 232-233 (1980)
- Green AR, Hall JE & Rees AR
A behavioural and biochemical study in rats of 5-hydroxytryptamine agonists and antagonists with observations on structure-activity requirements for the agonists. *Br J Pharmacol* 73: 703-720 (1981)
- Green AR
Pharmacological studies on serotonin-mediated behaviour. *J Physiol (Paris)* 77: 437-447 (1981)
- Cowen PJ, Green AR, Nutt DJ & Martin IL
Ethyl β -carboline carboxylate lowers seizure threshold and antagonises flurazepam-induced sedation in rats. *Nature* 290: 54-55 (1981)
- Nutt DJ, Cowen PJ & Green AR
Studies on the post-ictal rise in seizure threshold. *Eur J Pharmacol* 71: 287-295 (1981)
- Heal DJ, Akagi H, Bowdler JM & Green AR
Repeated electroconvulsive shock attenuates clonidine-induced hypoactivity in rodents. *Eur J Pharmacol* 75: 231-237 (1981)
- Heal DJ, Sabbagh A, Youdim MBH & Green AR
Behavioural effects of central and peripheral injection of various analogues and metabolites of thyrotropin releasing hormone. *Neuropharmacology* 20: 947-957 (1981)

- Bell FR, Green AR, Wass JAH & Webber DT
Intestinal control of gastric function in the calf - the relationship of neural and endocrine factors. *J Physiol* 321: 603-610 (1981)
- Nutt DJ, Cowen PJ, Batts CC, Grahame-Smith DG & Green AR
Repeated administration of GABA-antagonist drugs at sub-convulsant doses I: effect on seizure threshold (kindling). *Psychopharmacology* 76: 84-87 (1982)
- Cowen PJ, Nutt DJ, Batts CC, Green AR & Heal DJ
Repeated administration of GABA-antagonist drugs at sub-convulsant doses II: effect of monoamine-mediated behaviour. *Psychopharmacology* 76: 88-91 (1982)
- Bowdler JM & Green AR
Regional rat brain benzodiazepine receptor number and g-aminobutyric acid concentration following a convulsion. *Br J Pharmacol* 76: 291-298 (1982)
- Bax NDS, Boulton AJM, Woods HF & Green AR
Clinical and biochemical effects of parachlorophenylalanine in a patient with the carcinoid syndrome. *Postgrad Med J* 58: 493-495 (1982)
- Cowen PJ, Grahame-Smith DG, Green AR & Heal DJ
 β -adrenoceptor agonists enhance 5-hydroxytryptamine mediated behavioural responses. *Br J Pharmacol* 76: 265-270 (1982)
- Green AR, Sant K, Bowdler JM & Cowen PJ
Further evidence for a relationship between changes in GABA concentration in rat brain and enhanced monoamine-mediated behaviour following repeated electroconvulsive shock. *Neuropharmacology* 21: 981-984 (1982)
- Green AR, Nutt DJ & Cowen PJ
Benzodiazepines, benzodiazepine antagonists and the benzodiazepine receptor. *Oxford Med Sch Gazette* 33: 5-8 (1982)
- Green AR, Nutt DJ & Cowen PJ
Using Ro 15-1788 to investigate the benzodiazepine receptor *in vivo*: studies on the anticonvulsant and sedative effect of melatonin and the convulsant effect of the benzodiazepine Ro 05-3663. *Psychopharmacology* 78: 293-295 (1982)
- Green AR
The pharmacology basis of electroconvulsive therapy. *Oxford Med Sch Gazette* 32: 22-24 (1982)
- Minchin MCW, Williams J, Bowdler JM & Green AR
The effect of electroconvulsive shock on the uptake and release of noradrenaline and 5-hydroxytryptamine in rat brain slices. *J Neurochem* 40: 765-768 (1983)
- Bowdler JM, Green AR, Minchin MCW & Nutt DJ
Regional GABA concentration and [3 H]-diazepam binding in rat brain following repeated electroconvulsive shock. *J Neural Transm* 56: 3-12 (1983)
- Cowen PJ, Fraser S, Grahame-Smith DG, Green AR & Stanford C
The effect of chronic antidepressant administration on β -adrenoceptor function of the rat pineal. *Br J Pharmacol* 78: 89-96 (1983)
- Cowen PJ, Fraser S, Sammons R & Green AR
Atenolol reduces plasma melatonin concentration in man. *Br J Clin Pharmacol* 15: 579-581 (1983)
- Nimgaonkar VL, Green AR, Cowen PJ, Heal DJ, Grahame-Smith DG & Deakin JFW
Studies on the mechanisms by which clenbuterol, a β -adrenoceptor agonist, enhances 5-HT-mediated behaviours and increases brain 5-HT metabolism in the rat. *Neuropharmacology* 22: 739-749 (1983)

- Heal DJ, Lister S, Snith SL, Davies CL, Molyneux SG & Green AR
The effects of acute and repeated administration of various antidepressants on clonidine-induced hypoactivity in mice and rats. *Neuropharmacology* 22: 938-992 (1983)
- Green AR, Johnson P & Nimgaonkar VL
Interactions of β -adrenoceptor agonists and antagonists with the 5-hydroxytryptamine₂ (5-HT₂) receptor. *Neuropharmacology* 22: 657-660 (1983)
- Green AR, Johnson P & Nimgaonkar VL
Increased 5-HT₂ receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine mediated behaviour following repeated electroconvulsive shock administration to rats. *Br J Pharmacol* 80: 173-177 (1983)
- Green AR, O'Shaughnessy K, Hammond M, Schachter M & Grahame-Smith DG
Inhibition of 5-hydroxytryptamine mediated behaviours by the putative 5-HT₂ antagonist pirenperone. *Neuropharmacology* 22: 573-578 (1983)
- Green AR, Heal DJ, Johnson P, Laurence BE & Nimgaonkar VL
Antidepressant treatments: effects in rodents on dose responses curves of 5-hydroxytryptamine and dopamine mediated behaviour and 5-HT₂ receptor number in frontal cortex. *Br J Pharmacol* 80: 377-385 (1983)
- Green AR, Guy AP & Gardner CR
The behavioural effects of RU 24969, a 5-HT₁ receptor agonist in rodents and the effect on the behaviour of various antidepressant treatments. *Neuropharmacology* 23: 655-661 (1984)
- File SE, Green AR, Nutt DJ & Vincent ND
On the convulsant action of Ro 5-4864 and the existence of a micromolar benzodiazepine binding site in rat brain. *Psychopharmacology* 82: 199-202 (1984)
- File SE & Green AR
Repeated electroconvulsive shock has no specific anxiolytic effect but reduces social interaction and exploration in rats. *Neuropharmacology* 23: 93-95 (1984)
- Lighton C, Marsden CA, Bennett GW, Minchin MCW & Green AR
Decrease in levels of thyrotrophin-releasing hormone (TRH) in the n. accumbens and lumbar spinal cord following repeated electroconvulsive shock. *Neuropharmacology* 23: 963-966 (1984)
- Johnston BM, Walker DW & Green AR
Lack of long term effect of p-chlorophenylalanine on brain 5-hydroxytryptamine and electrocortical activity in conscious fetal sheep. *Experientia* 40: 291-294 (1984)
- Mellanby J, Green AR, Impey L, Oates C & Traynor L
The effect of electroconvulsive shock on learning and memory in rats. *Acta Neurol Scand* 69: Suppl 99, 115-118 (1984)
- Goodwin GM, Green AR & Johnston P
5-HT₂ receptor characteristics in frontal cortex and 5-HT₂ receptor mediated head-twitch behaviour following antidepressant treatment to mice. *Br J Pharmacol* 83: 235-242 (1984)
- Green AR
5-HT mediated behaviour: animal studies. *Neuropharmacology* 23: 1521-1528 (1984)

- Green AR
Antidepressant treatments and the serotonin receptor. *Acta Pharmacol Toxicol* 56: Suppl 1, 128-137 (1985)
- Green AR, Aronson JK & Cowen PJ
The pharmacokinetics of L-tryptophan following its intravenous and oral administration. *Br J Clin Pharmacol* 20: 317-321 (1985)
- Green AR & Mountford JM
Benzodiazepine administration to mice prevents some of the changes in monoamine-mediated behaviour produced by repeated electroconvulsive shock treatment. *Psychopharmacology* 86: 190-193 (1985)
- Green AR, Johnson P, Mountford JM & Nimgaonkar VL
Some anticonvulsant drugs alter monoamine behaviour in mice in ways similar to electroconvulsive shock: implications for antidepressant therapy. *Br J Pharmacol* 84: 337-346 (1985)
- Goodwin GM, De Souza RJ & Green AR
Presynaptic serotonin receptor-mediated response in mice attenuated by antidepressant drugs and electroconvulsive shock. *Nature* 317: 531-533 (1985)
- Goodwin GM, De Souza RJ & Green AR
The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a model of presynaptic 5-HT₁ function. *Neuropharmacology* 24: 1187-1194 (1985)
- Goodwin GM & Green AR
A behavioural and biochemical study in mice and rats of putative selective agonists for 5-HT₁ and 5-HT₂ receptors. *Br J Pharmacol* 84: 743-753 (1985)
- Nimgaonkar VL, Goodwin GM, Davies CL & Green AR
Down regulation of β -adrenoceptors in rat cortex by repeated administration of desipramine, electroconvulsive shock and clenbuterol requires 5-HT neurones but not 5-HT. *Neuropharmacology* 24: 279-283 (1985)
- Metz A, Goodwin GM & Green AR
The administration of baclofen to mice increase 5-HT₂-mediated behaviour and 5-HT₂ receptor number in frontal cortex. *Neuropharmacology* 24: 357-360 (1985)
- Cowen PJ, Green AR, Grahame-Smith DG & Braddock LE
Plasma melatonin during desipramine treatment: evidence for changes in noradrenergic transmission. *Br J Clin Pharmacol* 19: 799-805 (1985)
- Bennett GW, Green AR, Lighton C & Marsden CA
Changes in the behavioural response to a TRH analogue following chronic amitriptyline treatment and repeated electroconvulsive shock in the rat. *Br J Pharmacol* 88: 129-139 (1986)
- Cowen PJ, Geaney DP, Schachter M, Green AR & Elliott JM
Desmethylimipramine treatment in normal subjects: effects in neuroendocrine responses to L-tryptophan and platelet 5-HT-related receptors. *Arch Gen Psychiat* 43: 61-67 (1986)
- Gray JA, Metz A, Goodwin GM & Green AR
The effects of the GABA-mimetic drugs progabide and baclofen on 5-hydroxytryptamine and noradrenaline biochemistry and function. *Neuropharmacology* 25: 711-716 (1986)

- Green AR, Goodwin GM, De Souza RJ & Heal DJ
The β -adrenoceptor agonists clenbuterol and salbutamol enhance the hypothermic action of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in mice by a central mechanism. *Neuropharmacology* 25: 21-24 (1986)
- Appleyard ME, Green AR & Smith AD
Acetylcholinesterase activity in regions of rat brain following a convulsion. *J Neurochem* 46: 1789-1793 (1986)
- Nimgaonkar VL, Heal DK, Davies CL & Green AR
Studies on rat brain catecholamine synthesis and β -adrenoceptor number following administration of electroconvulsive shock, desipramine and clenbuterol. *J Neural Transm* 65: 245-259 (1986)
- Green AR
Changes in g-aminobutyric acid biochemistry and seizure threshold. *Ann N Y Acad Sci* 426: 105-119 (1986)
- De Souza RJ, Goodwin GM, Green AR & Heal DJ
Effect of chronic treatment with 5-HT₁ agonist (8-OH-DPAT and RU24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT₁ and 5-HT₂ agonists. *Br J Pharmacol* 89: 377-384 (1986)
- Wood AJ, Goodwin GM, De Souza RJ & Green AR
The pharmacokinetic profile of lithium in rat and mouse: an important factor in psychopharmacological investigations. *Neuropharmacology* 25: 1285-1288 (1986)
- Goodwin GM, De Souza RJ, Wood AJ & Green AR
Lithium decreases 5-HT_{1A} and 5-HT₂ receptor and α_2 -adrenoceptor-mediated function in mice. *Psychopharmacology* 90: 482-487 (1986)
- Goodwin GM, De Souza RJ, Green AR & Wood AJ
The enhancement by lithium of the 5-HT_{1A} mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. *Psychopharmacology* 90: 488-493 (1986)
- Goodwin GM, De Souza RJ & Green AR
Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT_{1A} receptor mediated hypothermic and serotonin syndrome produced by 8-OH-DPAT in the rat. *Psychopharmacology* 91: 500-505 (1987)
- Goodwin GM, De Souza RJ, Green AR & Heal DJ
The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). *Psychopharmacology* 91: 506-511 (1987)
- Green AR
Evolving concepts on the interactions between antidepressant treatments and monoamine neurotransmitters. *Neuropharmacology* 26: 815-822 (1987)
- Green AR, Metz A, Minchin MCW & Vincent ND
Inhibition of the rate of GABA synthesis in regions of rat brain following a convulsion. *Br J Pharmacol* 92: 5-11 (1987)
- Green AR, Minchin MCW & Vincent ND
Inhibition of GABA release from slices prepared from several brain regions of rats at various times following a convulsion. *Br J Pharmacol* 92: 13-18 (1987)
- Green AR & Vincent ND
The effect of repeated electroconvulsive shock on GABA synthesis and release in regions of rat brain. *Br J Pharmacol* 92: 19-24 (1987)

- Green AR, Heal DJ & Vincent ND
The effect of single and repeated electroconvulsive shock administration on the release of 5-hydroxytryptamine and noradrenaline from cortical slices of rat brain. *Br J Pharmacol* 92: 25-30 (1987)
- Appleyard ME, Green AR & Greenfield SA
Acetylcholinesterase activity rises in rat cerebrospinal fluid post-ictally: effect of a substantia nigra lesion this rise and on seizure threshold. *Br J Pharmacol* 91: 149-154 (1987)
- Gray JA & Green AR
GABA_B-receptor mediated inhibition of potassium evoked release of endogenous 5-hydroxytryptamine from mouse frontal cortex. *Br J Pharmacol* 91: 517-522 (1987)
- Gray JA & Green AR
Increased GABA_B receptor functions in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shocks. *Br J Pharmacol* 92: 357-362 (1987)
- Gray JA, Goodwin GM, Heal DJ & Green AR
Hypothermia induced by baclofen, a possible index of GABA_B receptor function in mice, is enhanced by antidepressant drugs and ECS. *Br J Pharmacol* 92: 863-870 (1987)
- Appleyard ME & Green AR
Acetylcholinesterase activity in regions of rat brain following repeated administration of electroconvulsive shock. *J Psychopharmacol* 1: 211-215 (1987)
- Green AR
The mechanism of action of antidepressant drugs: basic aspects. *Pharmacopsychiat* 21: 3-5 (1988)
- Stirling JM, Cross AJ & Green AR
[³H]-[1-(2-thienyl)-cyclohexyl]piperidine binding to the N-methyl-D-aspartic-acid receptor complex. *Biochem Soc Trans* 16: 300-301 (1988)
- Green AR
Recent preclinical studies on neurotransmitter function after ECS. *Psychopharmacol Bull* 24: 387-390 (1988)
- Stirling JM, Cross AJ & Green AR
The binding of [³H]-thienyl cyclohexylpiperidine ([³H]-TCP) to the NMDA-phenylclidine receptor complex. *Neuropharmacology* 28: 1-7 (1989)
- Stirling JM, Cross AJ, Robinson TN & Green AR
The effects of GABA_B receptor agonists and antagonists on potassium stimulated [Ca²⁺]_i in rat brain synaptosomes. *Neuropharmacology* 28: 699-704 (1989)
- Cross AJ, Stirling JM, Robinson TN, Bowen DM, Francis PJ & Green AR
The modulation by chlormethiazole of the GABA_A receptor complex in rat brain. *Br J Pharmacol* 98: 284-290 (1989)
- Hunter AJ, Murray TK, Jones JA, Cross AJ & Green AR
The cholinergic pharmacology of tetrahydroaminoacridine *in vivo* and *in vitro*. *Br J Pharmacol* 98: 79-86 (1989)
- Robinson TN, Cross AJ, Green AR, Toczek JM & Boar BR.
Effects of the putative antagonist phaclofen and d-amino valeric acid on GABA_B receptor biochemistry. *Br J Pharmacol* 98: 833-840 (1989)

- Robinson TN, De Souza RJ, Cross AJ & Green AR
The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms. *Br J Pharmacol* 98: 1127-1136 (1989)
- Green AR & Murray TK
A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms. *J Pharm Pharmacol* 41: 879-880 (1989)
- Green AR & Backus LI
Animals models of serotonin behaviour. *Ann N Y Acad Sci* 600: 237-248 (1990)
- Green AR, Davies EM, Little HJ, Whittington MA & Cross AJ
The action of chlormethiazole in a model of ethanol withdrawal. *Psychopharmacology* 102: 239-242 (1990)
- Green AR, De Souza RJ, Davies EM & Cross AJ
The effects of Ca²⁺ antagonists and hydralazine on central 5-hydroxytryptamine biochemistry and function in rats and mice. *Br J Pharmacol* 99: 41-46 (1990)
- Robinson TN, Robertson C, Cross AJ & Green AR
Modulation of [³H]-dizocilpine ([³H]-MK801) binding to rat cortical N-methyl-D-aspartate receptors by polyamines. *Molecular Neuropharmacology* 1: 31-35 (1990)
- Steele JE, Bowen DM, Francis PT, Green AR & Cross AJ
Spermidine enhancement of [³H]-MK801 binding to the NMDA receptor complex in human cortical membranes. *Eur J Pharmacol* 189: 195-200 (1990)
- Baldwin HA, De Souza RJ, Sarna GS, Murray TK, Green AR & Cross AJ
Measurements of tacrine and monoamines in brain by *in vivo* microdialysis argue against tacrine releasing monoamines at therapeutic doses. *Br J Pharmacol* 103: 1946-1950 (1991)
- Cross AJ, Jones JA, Baldwin HA & Green AR
Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. *Br J Pharmacol* 104: 406-411 (1991)
- Murray TK, Cross AJ & Green AR
Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats. *Psychopharmacology* 105: 134-136 (1991)
- Steele JE, Robinson TN, Cross AJ, Bowen DM & Green AR
A comparison of [³H]-MK801 and N-[1-(2-thienyl) cyclohexyl]-3,4-[³H]piperidine binding to the N-methyl-D-aspartate receptor complex in human brain. *J Neurochem* 56: 1248-1254 (1991)
- Green AR
Do benzodiazepines interfere with the action of ECT? *Br J Psychiat* 161: 129-130 (1992)
- Green AR, Cross AJ, Snape MF & De Souza RJ
The immediate consequences of middle cerebral artery occlusion on GABA synthesis in mouse cortex and cerebellum. *Neurosci Letts* 138: 141-144 (1992)
- Green AR, De Souza RJ & Cross AJ
Studies on the enhancement of 5-hydroxytryptamine-mediated behaviour by chlormethiazole and phenytoin. *J Psychopharmacol* 6: 370-375 (1992)

- Green AR, De Souza RJ, Williams JL, Murray TK & Cross AJ
The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in the brain: evidence for the protective effect of chlormethiazole. *Neuropharmacology* 31: 315-321 (1992)
- Baldwin HA, Colado MI, Murray TK, De Souza RJ & Green AR
Striatal dopamine release *in vivo* following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. *Br J Pharmacol* 108: 590-596 (1993)
- Baldwin HA, Jones JA, Cross AJ & Green AR
Histological, biochemical and behavioural evidence for the neuroprotective action of chlormethiazole following prolonged carotid artery occlusion. *Neurodegeneration* 2: 139-146 (1993)
- Baldwin HA, Jones JA, Snares M, Williams JL, Cross AJ & Green AR
Investigation of the role of 5-hydroxytryptamine in a model of focal cerebral ischaemia in the rat. *Neurodegeneration* 2: 33-40 (1993)
- Baldwin HA, Snape MF, Williams JL, Misra A, Jones JA, Snares M, Green AR & Cross AJ
The role of glutamate and GABA in a rat model of focal cerebral ischaemia: biochemical and pharmacological investigations. *Neurodegeneration* 2: 129-138 (1993)
- Colado MI, Murray TK & Green AR
5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. *Br J Pharmacol* 108: 583-589 (1993)
- Cross AJ, Misra A, Sandilands A, Taylor MJ & Green AR
Effect of chlormethiazole, dizocilpine and pentobarbital on harmaline-induced increase of cerebellar cyclic GMP and tremor. *Psychopharmacology* 111: 96-98 (1993)
- Cross AJ, Snape MF & Green AR
Chlormethiazole antagonises seizures induced by N-methyl-DL-aspartate without interacting with the NMDA receptor complex. *Psychopharmacology* 112: 403-406 (1993)
- Francis PT, Webster M-T, Chessell IP, Holmes C, Stratmann GC, Procter AW, Cross AJ, Green AR & Bowen DM
Neurotransmitters and second messengers in aging and Alzheimer's disease. *Ann NY Acad Sci* 695: 19-26 (1993)
- Rose S, Jenner P & Green AR
Chlormethiazole does not protect against the dopaminergic neurotoxicity induced by intranigral injection of MPP+ in rats. *Neurodegeneration* 2: 267-273 (1993)
- Snape MF, Baldwin HA, Cross AJ, Green AR
The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat. *Neuroscience* 53: 837-844 (1993)
- Baldwin HA, Williams JL, Snares M, Ferreira T, Cross AJ & Green AR
Attenuation by chlormethiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat. *Br J Pharmacol* 112: 188-194. (1994)

- Colado MI & Green AR
A study of the mechanism of MDMA ('Ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. *Br J Pharmacol* 111: 131-136 (1994)
- Green AR & Cross AJ
Attenuation by chlormethiazole of oedema following focal ischaemia in the cerebral cortex of the rat. *Neurosci Letts* 173: 27-30 (1994)
- Snape MF, Colado MI & Green AR
Chlormethiazole and dizocilpine block the behavioural, but not the neurotoxic effects of 5,7-dihydroxytryptamine in mice. *Pharmacol Toxicol* 74: 40-42 (1994)
- Watson WP, Misra A, Cross AJ, Green AR & Little HJ
The differential effect of felodipine and nitrendipine on cerebral dihydropyridine binding ex vivo and the ethanol withdrawal syndrome in mice. *Br J Pharmacol* 112: 1017-1024 (1994)
- Hewitt KE & Green AR
Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. *Neuropharmacology* 33: 1589-1595 (1994)
- Green AR & Cross AJ
The neuroprotective actions of chlormethiazole. *Progr Neurobiol* 44: 463-484 (1994)
- Sydserrff SG, Cross AJ, West KJ & Green AR
The effect of chlormethiazole on neuronal damage in a model of transient focal ischaemia. *Br J Pharmacol* 114: 1631-1635 (1995)
- Cross AJ, Jones JA, Snares M, Jostell K-G, Bredberg U & Green AR
The protective action of chlormethiazole against ischaemia-induced neurodegeneration in gerbils when infused at doses having little sedative or anticonvulsant activity. *Br J Pharmacol* 114: 1625-1630 (1995)
- Hunter AJ, Green AR & Cross AJ
Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? *Trends Pharmacol Sci* 16: 123-128 (1995)
- Colado MI, Williams JL & Green AR
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metaboliser phenotype. *Br J Pharmacol* 115: 1281-1289 (1995)
- Colado MI & Green AR
The spin trap reagent a-phenyl-N-tert butyl nitron (PBN) prevents 'Ecstasy'-induced neurodegeneration of 5-HT neurones. *Eur J Pharmacol* 280: 343-346 (1995)
- Sydserrff SG, Cross AJ & Green AR
The neuroprotective effect of chlormethiazole on ischaemic neuronal damage following permanent middle cerebral artery ischaemia in the rat. *Neurodegeneration* 4: 323-328 (1995)
- Green AR, Cross AJ & Goodwin GM
Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). *Psychopharmacology* 119: 247-260 (1995)

- Syderff SG, Green AR & Cross AJ
The effect of oedema and tissue swelling on the measurement of neuroprotection; a study using chlormethiazole and permanent middle cerebral artery occlusion in rats. *Neurodegeneration* 5: 81-85 (1996).
- Green AR
Narrative, history and accuracy. *J Psychopharmacol* 10: 70 (1996)
- Green AR & Goodwin GM
Ecstasy and neurodegeneration *Br Med J* 312: 1493-1494 (1996)
- Green AR, Misra A, Murray TK, Snape MF & Cross AJ
A behavioural and neurochemical study in rats of the pharmacology of loreclezole, a novel allosteric modulator of the GABA_A receptor. *Neuropharmacology* 35: 1243-1250 (1996)
- Murray TK, Williams JL, Misra A, Colado MI & Green AR
The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine. *Neuropharmacology* 35: 1615-1620 (1996)
- Colado MI, O'Shea E, Granados R, Misra A, Murray TK & Green AR
A study of the neurotoxic effect of 'ecstasy' (MDMA) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. *Br J Pharmacol* 121: 827-833 (1997)
- Colado MI, O'Shea E, Granados R, Murray TK & Green AR
In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT neurons which follows administration of MDMA ('ecstasy') but not the degeneration which follows fenfluramine. *Br J Pharmacol* 121: 889-900 (1997)
- Colado MI, Granados R, O'Shea E, Estaban B & Green AR
The role of hyperthermia in the mechanism of protection by clomethiazole against MDMA ("ecstasy")-induced neurodegeneration, comparison with the novel NMDA antagonist AR-R15896AR. *Br. J. Pharmacol.* 124: 479-484 (1998)
- O'Shea E, Granados R, Estaban B, Colado MI & Green AR
The relationship between the degree of neurodegeneration of rat brain 5-HT terminals and the dose and frequency of administration of MDMA ("ecstasy"). *Neuropharmacology*. 37: 919-926 (1998)
- Green AR, Misra A, Hewitt KE, Snape MF & Cross AJ
An investigation of the possible interaction of clomethiazole with glutamate and ion channel sites as an explanation of its neuroprotective activity. *Pharmacol Toxicol* 83: 90-94 (1998).
- Green AR
Clomethiazole (Zendra®) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy. *Pharmacol Ther* 80: 123-147 (1998).
- Colado MI, O'Shea E, Granados R & Green AR
In vivo evidence against clomethiazole being protective against MDMA ("ecstasy")-induced degeneration of rat brain 5-HT by a free radical scavenging mechanism. *Neuropharmacology* 38: 307-314 (1999)
- Colado MI, O'Shea E, Granados R, Estaban B, Martin AB & Green AR
Studies on the role of dopamine in the degeneration of rat brain 5-HT following administration of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). *Br J Pharmacol* 126: 911-924 (1999)

- Colado MI, Esteban B, O'Shea E, Granados R & Green AR
Studies on the protective effect of pentobarbitone on MDMA-induced neurodegeneration. *Psychopharmacology* 142: 421-425 (1999)
- Snape MF, Misra A, Murray TK, Cross AJ & Green AR
A comparative study in rats of the *in vitro* and *in vivo* pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. *Neuropharmacology* 38: 181-193 (1999)
- Colado MI, Granados R, O'Shea E, Esteban B & Green AR
The acute effects in rats of 3,4-methylenedioxyethamphetamine (MDEA or "eve") on body temperature and long term degeneration of 5-HT neurones in brain; a comparison with MDMA ("ecstasy"). *Pharmacol Toxicol* 84: 261-266 (1999)
- Green AR, Murray TK, Misra A, Snape MF & Cross AJ
The metabolism of clomethiazole in gerbils and the neuroprotective and sedative activity of the metabolites. *Br J Pharmacol* 129: 95-100 (2000)
- Green AR, Hainsworth, AH & Jackson DM
GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. *Neuropharmacology* 39: 1483-1494 (2000)
- Dronfield S, Egan K, Marsden CA & Green AR
Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. *J Psychopharmacol* 14: 275-279 (2000)
- Marshall JWB, Cross AJ, Jackson DM, Green AR, Baker HF & Ridley RM
Clomethiazole protects against ischaemia-induced hemineglect in a primate model of stroke. *Brain Res Bull* 52: 21-29 (2000)
- Sydserrff SG, Cross AJ, Murray TK, Jones JA & Green AR
Clomethiazole is neuroprotective in models of global and focal ischemia when infused at doses producing clinically relevant plasma concentrations. *Eur J Pharmacol* 862: 59-62 (2000)
- Nelson RM, Green AR, Lambert DG, Hainsworth AH
On the regulation of ischaemia-induced glutamate efflux from rat cortex by GABA; *in vitro* studies with GABA, clomethiazole and pentobarbitone. *Br J Pharmacol* 130: 1124-1130 (2000)
- Nelson RM, Calo G, Guerrini R, Hainsworth AH, Green AR & Lambert DG
Nociceptin/orphanin FQ inhibits ischaemia-induced glutamate efflux from rat cerebrocortical slices. *NeuroReport* 11: 3689-3692 (2000)
- Peeling J, Del Bigio MR, Corbett D, Green AR & Jackson DM
Efficacy of disodium 4-[(*tert*-butylimino)methyl] benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. *Neuropharmacology* 40: 433 – 439 (2001)
- O'Shea E, Esteban B, Camarero J, Green AR & Colado MI
Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. *Neuropharmacology* 40 65-74 (2001)
- Marshall JWB, Duffin J, Green AR & Ridley RM
NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. *Stroke* 32: 190-198 (2001)

- Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR & Colado MI
3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. *Psychopharmacology* 154: 251-260 (2001)
- Mechan AO, O'Shea E, Elliott JM, Colado MI & Green AR
A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation. *Psychopharmacology* 155: 413-418 (2001)
- Colado MI, O'Shea E, Esteban B & Green AR
Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA ("ecstasy")-induced neurodegeneration in rat brain. *Psychopharmacology* 157: 82-88 (2001)
- Nelson RM, Hainsworth AH, Lambert DG, Jones JA, Murray TK, Richards DA, Gabrielsson J, Cross AJ & Green AR
Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and on ischaemia-induced glutamate and GABA efflux in vitro. *Neuropharmacology* 41: 159-166 (2001)
- Green AR, Hainsworth AH, Misra A, Debens TA, Jackson DM, Murray TK, Nelson RM & Cross AJ
The interaction of AR-A008055 and its enantiomers with the GABA_A receptor complex and their sedative, muscle relaxant and anticonvulsant activity. *Neuropharmacology* 41: 167-174 (2001)
- Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR & Colado MI
The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. *Br J Pharmacol* 134: 46-57 (2001)
- Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, Green AR
A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) on dopamine neurones in mouse brain. *Br J Pharmacol* 134: 1711-1723 (2001)
- Mechan AO, Esteban B, O'Shea E, Elliott JM, & Green AR
The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. *Br J Pharmacol* 135: 170-180 (2002)
- Sydserrff SG, Borelli AR, Green AR & Cross AJ
Effect of NXY-059 on infarct volume following both transient and permanent occlusion of the middle cerebral artery in the rat; studies on dose, plasma concentration and therapeutic time window. *Br J Pharmacol* 135: 103-112 (2002)
- Mechan AO, Moran PM, Elliott JM, Young AMJ, Joseph MH & Green AR
A study of the long-term effects of a neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') on the behaviour of rats in the plus maze and open field. *Psychopharmacology* 159: 167-175 (2002)
- Mechan AO, Moran PM, Elliott JM, Young AMJ, Joseph MH & Green AR
A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and in their response to diazepam. *Psychopharmacology* 159: 188-195 (2002)

- Camarero J, Sanchez V, O'Shea, Green AR, Colado MI
 Studies, using *in vivo* microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy')-induced dopamine release and free radical formation in the mouse striatum. *J Neurochem* 81: 961-972 (2002)
- O'Shea EO, Easton N, Fry JR, Green AR, Marsden CA
 Protection against, 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia. *J. Neurochem* 81: 686-695 (2002)
- Green, AR, McGregor IS
 On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. *Psychopharmacology* 162: 448-450 (2002)
- Green, AR
 Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. *Clin Exp Physiol Pharmacol* 29: 1030-1034 (2002)
- Dehouck MP, Cecchelli R, Green AR, Renftel M, Lundquist L
In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. *Brain Res* 955: 229-235 (2002)
- Nelson RM, Green AR, Hainsworth AH
 Electrophysiological actions of GABA and clomethiazole on recombinant GABA_A receptors. *Eur J Pharmacol* 452: 255-262 (2002)
- Nelson RM, Lambert DG, Green AR, Hainsworth AH
 Pharmacology of ischemia-induced glutamate efflux from rat cerebral cortex in vitro. *Brain Res* 964: 1-8 (2003)
- Nelson RM, Lambert DG, Green AR, Hainsworth AH
 Ischaemia-induced glutamate efflux from rat cerebrocortical tissue in vitro: effects of ion channel blockers, the glutamate transporter antagonist TBOA and glutamate receptor sub-type ligands. *Brain Res* 964: 1-8 (2003)
- Marshall JWB, Green AR, Ridley RM
 Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. *Brain Res* 972: 119-126 (2003)
- Sanchez V, Camarero J, O'Shea E, Green AR, Colado MI
 Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. *Neuropharmacology* 44: 449-461 (2003)
- O'Shea E, Sanchez V, Camarero J, Green AR, Colado MI
 On the protection against methamphetamine-induced neurotoxicity by benzamide, a PARP inhibitor. *Psychopharmacology* 165: 317-319 (2003)
- Sanchez V, Camarero J, O'Shea E, Green AR, Colado MI
 Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. *Neuropharmacology* 44: 449-461 (2003)
- Sanchez V, Zeini M, Camarero J, O'Shea E, Bosca L, Green AR, Colado MI
 The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse strain. *J Neurochem* 85: 515-524 (2003)

- Marshall JWB, Green AR, Ridley RM
Comparison of the neuroprotective effect of clomethiazole, AR-R15896 and NXY-059 in a primate model of stroke using histological and behavioural measures. *Brain Res* 972: 119-126 (2003)
- Marshall JWB, Cummings RM, Bowes LJ, Ridley RM, Green AR
Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. *Stroke* 34: 2228-2233 (2003)
- Green AR, Odergren T, Ashwood T
Animal models of stroke: do they have value for discovering neuroprotective agents? *Trends in Pharmacol Sci* 24: 402-408 (2003)
- Green AR, Mehan AO, Elliott JM, O'Shea E & Colado MI
The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). *Pharmacol Revs* 55: 463-508 (2003)
- Green AR, Ashwood T, Odergren T & Jackson DM
Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. *Pharmacol Ther* 100: 195-214 (2003)
- Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM & Colado MI
Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. *Psychopharmacology* 173: 264-269 (2004)
- Maples KR, Green AR & Floyd RA
Nitron-related therapeutics: Potential in the treatment of neurological disorders. *CNS Drugs* 18: 1071-1084 (2004)
- Beveridge TJR, Mehan AO, Sparkes M, Pei Q, Zetterstrom TSC, Green AR & Elliott JM
Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain. *Psychopharmacology* 173: 346-352 (2004)
- Colado MI, O'Shea E & Green AR
Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. *Psychopharmacology* 173: 249-263 (2004)
- Saadat KS, Elliott JM, Colado MI & Green AR
Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs. *Psychopharmacology* 173: 452-453 (2004)
- Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI & Green AR
Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. *J Psychopharmacol* 18: 412-416 (2004)
- Green AR
MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press. *Psychopharmacology* 173: 231-233 (2004)
- Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR & Colado MI
3,4-Methylenedioxymethamphetamine increases interleukin-1 β levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. *J Neurochem* 89: 1445-1453 (2004)

- Green AR, O'Shea E & Colado MI
A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. *Eur J Pharmacol* 500: 3-13 (2004)
- Green AR
Protecting the brain: The search for a clinically effective neuroprotective drug for stroke. *Critical Reviews in Neurobiology* 16: 73-79 (2004)
- Green AR & Ashwood T
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers *Current Drug Targets-CNS & Neurological Disorders* 16:91-97 (2005)
- Escobedo I, O'Shea E, Orio L, Sanchez V, Segura M, de la Torre R, Farre M, Green AR & Colado MI
A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. *Br J Pharmacol* 144: 231-241 (2005)
- Saadat KS, O'Shea E, Colado MI, Elliott JM & Green AR
The role of 5-HT in the impairment of thermoregulation in MDMA ('ecstasy')-pretreated rats. *Psychopharmacology* 179: 884-890 (2005)
- O'Shea E, Escobedo I, Orio L, Sanchez V, Navarro M, Green AR & Colado MI
Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. *Neuropsychopharmacology* 30: 1312-1323 (2005)
- O'Shea E, Sanchez V, Orio L, Escobedo I, Green AR & Colado MI.
3,4-Methylenedioxymethamphetamine increases pro-interleukin-1 beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of dark agouti rats: Role of interleukin-1 beta in neurotoxicity. *Neuroscience*. **135**: 1095-1105 (2005).
- Green AR, O'Shea E, Saadat KS, Elliott JM & Colado MI.
Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient temperatures. *Br J Pharmacol* 146: 306-312(2005).
- Green AR
A brief history of British Pharmacological Society meetings. *Trends Pharmacol Sci* 27: 178-181 (2006)
- Green AR. (2006)
Neuropharmacology of 5-hydroxytryptamine. *Br J Pharmacol*. 147 (Suppl 1): S145-S152 (2006).
- Green AR, Lanbeck-Vallen K, Ashwood T, Lundquist S, Lindstrom-Böö E, Jonasson H & Campbell M.
Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia. *Brain Res*. **1072**: 224-226 (2006).
- Green AR & Shuaib A.
Therapeutic strategies for the treatment of stroke. *Drug Discovery Today*. 11: 681-693 (2006).
- O'Shea E, Orio L, Escobedo I, Sanchez V, Camarero J, Green AR & Colado MI.
MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. *Br J Pharmacol*. 148: 778-785 (2006).

- Hainsworth AH, Nelson RM, Lambert DG, Green AR & Webb TE
Glutamate receptor-mediated inhibition of L- glutamate efflux from cerebral cortex in vitro. *Brain Res* 1114: 36-40 (2006)
- Saadat KS, Elliott JM, Colado MI & Green AR.
The acute and long-term neurotoxic effects of MDMA on marble burying behaviour in mice. *J Psychopharmacol.* **20**: 264-271, (2006).
- Saadat KS, Elliott JM, Green AR & Moran PM.
High dose MDMA does not result in long-term changes in impulsivity in the rat. *Psychopharmacology* 188: 75-83 (2006).
- Wang C, Green AR & Shuaib A
Neuroprotection in stroke: what should we learn from the development of NXY-059. *Recent Res Devel Neurosci* 2: 2:1-16. (2007).
- Williams HE, Claybourn M & Green AR.
Investigating the free radical trapping ability of NXY-059, S-PBN and PBN. *Free Radic Res.*41:1047-1052 (2007).
- Green AR, Marsden CA, Mylecharane EJ.
The Serotonin Club: coming of age. *Trends Pharmacol Sci.* 29: 431-432 (2008).
- Green A, Marsden C, Fone K.
MDMA as a clinical tool: a note of caution. A response to Sessa and Nutt. *J Psychopharmacol.* 22: 929-931(2008).
- Green AR.
Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK. *Br J Pharmacol.* 154:1583-1599 (2008).
- Green AR.
Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. *Br J Pharmacol.* 153: S325-S338 (2008).
- Hensler JG & Green AR
The Serotonin Club at 21: United in diverse neuropharmacology. *Neuropharmacology* 55: 921 (2008).
- Mutch NJ, Moore NR, Mattsson C, Jonasson H, Green AR, Booth NA
The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro. *Br J Pharmacol.* 153:124-131 (2008).
- Hainsworth AH, Bhuiyan N, Green AR.
The nitron disodium 2,4-sulphophenyl-N-tert-butyl nitron is without cytoprotective effect on sodium nitroprusside-induced cell death in N1E-115 neuroblastoma cells in vitro. *J Cereb Blood Flow Metab* 2008 28: 24-28 (2008).
- Bath PM, Macleod MR, Green AR.
Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. *Int J Stroke.* 4:471-479 (2009).
- Gabrielsson J, Green AR.
Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. *J Pharmacol Exp Ther.* 331:767-74 (2009).
- Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. *Br J Pharmacol.* 157:1157-1171 (2009).

- Green AR, Gabrielsson J, Marsden CA, Fone KC.
MDMA: on the translation from rodent to human dosing. *Psychopharmacology* 204:375-378 (2009).
- Docherty JR, Green AR.
The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. *Br J Pharmacol.* 160:1029-44 (2010).
- Gabrielsson J, Green AR, Van der Graaf PH.
Optimising in vivo pharmacology studies--Practical PKPD considerations. *J Pharmacol Toxicol Methods.* 61:146-156 (2010).
- Rodsiri R, Green AR, Marsden CA, Fone KC.
Effect of acute brain tyrosine depletion on MDMA-induced changes in brain 5-HT. *J Psychopharmacol.* 24:267-74 (2010).
- Green AR, Gabrielsson J, Fone KC.
Translational neuropharmacology and the appropriate and effective use of animal models. *Br J Pharmacol.* 2011 Oct;164(4):1041-3 (2011).
- Rodsiri R, Spicer C, Green AR, Marsden CA, Fone KC.
Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. *Psychopharmacology* 213:365-76 (2011).
- Green AR, Aronson JK.
From basic to clinical neuropharmacology: targetophilia or pharmacodynamics? *Br J Clin Pharmacol.* 73:959-967 (2012).
- Green AR, King MV, Shortall SE, Fone KC.
Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. *Br J Pharmacol.* 166:1523-1536 (2012).
- Green AR, King MV, Shortall SE, Fone KC.
Ecstasy cannot be assumed to be 3,4-methylenedioxymethamphetamine (MDMA). *Br J Pharmacol* 166:1521-1522.
- Green AR, Marsden CA.
How do we re-engage the pharmaceutical industry in research on serotonin and psychiatric disorders? *ACS Chem Neurosci.* 4:9-12 (2013).
- Shortall SE, Green AR, Swift KM, Fone KC, King MV.
Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. *Br J Pharmacol.* 168: 966-977 (2013).
- Shortall SE, Macerola AE, Swaby RT, Jayson R, Korsah C, Pillidge KE, Wigmore PM, Ebling FJ, Green AR, Fone KC, King MV.
Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. *Eur Neuropsychopharmacol.* 23:1085-1095 (2013)
- Green AR, Nutt DJ.
Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). *J Psychopharmacol.* 28:711-718 (2014).
- Green AR, King MV, Shortall SE, Fone KC.
The preclinical pharmacology of mephedrone; not just MDMA by another name. *Br J Pharmacol.* 171:2251-2268 (2014).

O'Shea E, Urrutia A, Green AR, Colado MI.

Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine. *Neuropharmacology*. 87:125-134 (2014).

Jones S, Fileccia EL, Murphy M, Fowler MJ, King MV, Shortall SE, Wigmore PM, Green AR, Fone KC, Ebling FJ.

Cathinone increases body temperature, enhances locomotor activity, and induces striatal c-fos expression in the Siberian hamster. *Neurosci Lett*. 559: 34-38 (2014).

Shortall SE, Spicer CH, Ebling FJ, Green AR, Fone KC, King MV.

Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone.

Addict Biol. 2015 Jul 16. doi: 10.1111/adb.12283 (2015)